Monte Rosa Therapeutics (GLUE) Net Cash Flow (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Net Cash Flow of $30.0 million for Q1 2026, up 120.57% year-over-year from $13.6 million in Q1 2025, and up 138.2% quarter-over-quarter from -$78.5 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Net Cash Flow (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at $30.0 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 120.57% year-over-year to $30.0 million; the TTM figure through Mar 2026 stood at $81.4 million (up 483.85% YoY), while the FY2025 annual figure was -$94.3 million, down 197.76% from the prior year.
- Net Cash Flow for Q1 2026 stood at $30.0 million, up from -$78.5 million in the prior quarter.
- The five-year high for Net Cash Flow was $138.9 million in Q3 2025, with the low at -$207.8 million in Q1 2022.
- The 5-year median for Net Cash Flow is -$3.1 million (2023), against an average of -$11.0 million.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow slumped 816.59% in 2024, then surged 728.35% in 2025.
- Monte Rosa Therapeutics' Net Cash Flow stood at -$57.5 million in 2022, then soared by 220.25% to $69.1 million in 2023, then soared by 42.73% to $98.6 million in 2024, then sank by 179.54% to -$78.5 million in 2025, then jumped by 138.2% to $30.0 million in 2026.
- Business Quant data shows GLUE's Net Cash Flow at $30.0 million in Q1 2026, -$78.5 million in Q4 2025, and $138.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | -69.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -69.76 Mn |
| Jun 30, 2026 | -69.76 Mn |
| Mar 31, 2026 | 29.97 Mn |
| Mar 31, 2026 | 29.97 Mn |
| Dec 31, 2025 | -78.46 Mn |
| Dec 31, 2025 | -78.46 Mn |
| Sep 30, 2025 | 138.91 Mn |
| Sep 30, 2025 | 138.91 Mn |
| Jun 30, 2025 | -9.03 Mn |
| Jun 30, 2025 | -9.03 Mn |
| Mar 31, 2025 | -145.71 Mn |
| Mar 31, 2025 | -145.71 Mn |
| Dec 31, 2024 | 98.63 Mn |
| Dec 31, 2024 | 98.63 Mn |
| Sep 30, 2024 | 16.77 Mn |
| Sep 30, 2024 | 16.77 Mn |
| Jun 30, 2024 | 9.10 Mn |
| Jun 30, 2024 | 9.10 Mn |
| Mar 31, 2024 | -28.07 Mn |
| Mar 31, 2024 | -28.07 Mn |